Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Victory Capital Management Inc.

Key Points

• Victory Capital Management Inc. increased its stake in Janux Therapeutics by 9.6%, acquiring 23,242 shares and bringing its total to approximately $7.2 million worth of stock.
• Janux Therapeutics has experienced significant interest from institutional investors, with around 75.39% of its stock currently held by such entities.
• Raymond James Financial recently began coverage of Janux Therapeutics, assigning an "outperform" rating and setting a price target of $65.00 for the stock.

Victory Capital Management Inc. increased its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 265,651 shares of the company's stock after acquiring an additional 23,242 shares during the period. Victory Capital Management Inc. owned approximately 0.45% of Janux Therapeutics worth $7,173,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JANX. Russell Investments Group Ltd. boosted its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $59,000. GAMMA Investing LLC boosted its position in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after buying an additional 1,574 shares during the period. FNY Investment Advisers LLC boosted its position in shares of Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares during the period. Finally, KBC Group NV purchased a new position in shares of Janux Therapeutics during the first quarter valued at approximately $66,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Down 2.0%

Shares of JANX stock traded down $0.52 during trading hours on Tuesday, reaching $25.04. 223,214 shares of the company's stock were exchanged, compared to its average volume of 944,633. The stock's 50 day moving average is $24.83 and its 200-day moving average is $30.04. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -18.42 and a beta of 2.86. Janux Therapeutics, Inc. has a fifty-two week low of $22.48 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider directly owned 82,139 shares of the company's stock, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 29.40% of the company's stock.

Wall Street Analyst Weigh In

Separately, Raymond James Financial began coverage on Janux Therapeutics in a research report on Friday, July 11th. They set an "outperform" rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $91.89.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.